Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711824 | 1.00 | GAA (0.50) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL711315 | 1.00 | GAA (0.50) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL711316 | 1.00 | GAA (0.50) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL17189632 | 0.96 | GAA (0.47) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL3485952 | 0.94 | GAA (0.55) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL8226797 | 0.94 | GAA (0.55) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL8234372 | 0.94 | GAA (0.55) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL3485955 | 0.94 | GAA (0.55) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL12088621 | 0.89 | GAA (0.53) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL8234364 | 0.89 | GAA (0.51) | GAARAB9AALDH1A1LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315243-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LTD (AU) | 2015-11-05 | — | — | US | disclosed |
| US-9102708-B2 | Methods for the synthesis of dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2015-08-11 | — | — | US | disclosed |
| US-8759480-B2 | Contoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | SYNGENE LIMITED (AU) | 2014-06-24 | — | — | US | disclosed |
| US-20130123463-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LIMITED (AU) | 2013-05-16 | — | — | US | disclosed |
| US-8362204-B2 | Methods for the synthesis of two or more dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2013-01-29 | — | — | US | disclosed |
| US-20130023645-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| US-20120142892-A1 | CONTOXIN ANALOGUES AND METHODS FOR SYNTHESIS OF INTRAMOLECULAR DICARBA BRIDGE-CONTAINING PEPTIDES | POLYCHIP PHARMACEUTICALS PTY LTD. (AU) | 2012-06-07 | — | — | US | disclosed |
| US-8188217-B2 | — | — | 2012-05-29 | — | — | US | disclosed |
| US-8124726-B2 | Contoxin analogues and methods for synthesizing same | MONASH UNIVERSITY (AU) | 2012-02-28 | — | — | US | disclosed |
| US-8124726-B2 | Contoxin analogues and methods for synthesizing same | MONASH UNIVERSITY (AU) | 2012-02-28 | — | — | US | disclosed |
| US-7745573-B2 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | POLYCHIP PHARMACEUTICALS PTY LTD. (AU) | 2010-06-29 | — | — | US | disclosed |
| US-20100036089-A1 | Methods for the Synthesis of Dicarba Bridges in Organic Compounds | MONASH UNIVERSITY (AU) | 2010-02-11 | — | — | US | disclosed |
| US-20100022749-A1 | Contoxin Analogues and Methods for Synthesizing Same | MONASH UNIVERSITY (AU) | 2010-01-28 | — | — | US | disclosed |
| US-20100022749-A1 | Contoxin Analogues and Methods for Synthesizing Same | MONASH UNIVERSITY (AU) | 2010-01-28 | — | — | US | disclosed |
| US-20090143565-A1 | Methods for the Synthesis of Two or More Dicarba Bridges in Organic Compounds | SYNGENE LIMITED (AU) | 2009-06-04 | — | — | US | disclosed |
| US-20090143565-A1 | Methods for the Synthesis of Two or More Dicarba Bridges in Organic Compounds | SYNGENE LIMITED (AU) | 2009-06-04 | — | — | US | disclosed |
| US-20070197429-A1 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | SYNGENE LIMITED (AU) | 2007-08-23 | — | — | US | disclosed |
| WO-2007093013-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | MONASH UNIVERSITY (AU) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143565-A1 | Methods for the Synthesis of Two or More Dicarba Bridges in Organic Compounds | OTC, NBAS, IDH2 | GAA 3062/4885RAB9A 3416/4885ALDH1A1 838/4885 |
| US-20130023645-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | DCLRE1A, RNF168, CDCA2 | GAA 4501/4885RAB9A 2781/4885ALDH1A1 2184/4885 |
| US-20130123463-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | OTC, NBAS, IDH2 | GAA 3062/4885RAB9A 3416/4885ALDH1A1 838/4885 |
| US-20120142892-A1 | CONTOXIN ANALOGUES AND METHODS FOR SYNTHESIS OF INTRAMOLECULAR DICARBA BRIDGE-CONTAINING PEPTIDES | VIP, CANX, INHA | GAA 3224/4885RAB9A 2409/4885ALDH1A1 4754/4885 |
| US-20100022749-A1 | Contoxin Analogues and Methods for Synthesizing Same | VIP, CANX, PDIA5 | GAA 2733/4885RAB9A 2642/4885ALDH1A1 4713/4885 |
| US-20100036089-A1 | Methods for the Synthesis of Dicarba Bridges in Organic Compounds | DCLRE1A, RNF168, MTCL3 | GAA 4527/4885RAB9A 3002/4885ALDH1A1 2484/4885 |
| US-20150315243-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | DCLRE1A, RNF168, MTCL3 | GAA 4527/4885RAB9A 3002/4885ALDH1A1 2484/4885 |
| US-20070197429-A1 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | VIP, NRDC, INHA | GAA 3234/4885RAB9A 2984/4885ALDH1A1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.